Description

Boston Scientific: Penumbra Could Reshape Its Future — Will The Acquisition Deliver?

Boston Scientific Corporation reported first quarter 2026 organic revenue growth of 9.4%, aligning with the high end of its guidance range (8.5% to 10%). Adjusted earnings per share (EPS) increased 6% to $0.80, also at the top of its forecast, supported by an adjusted operating margin of 28%. Despite this solid start, the company revised downward its full-year 2026 organic revenue growth guidance to 6.5%–8%, citing unforeseen headwinds particularly impacting key segments and evolving business trends. Second quarter growth is expected to be weaker at 5%–7%, reflecting challenging sequential comparisons and transient market pressures. Adjusted EPS guidance for the full year was set at $3.34 to $3.41, representing 9% to 11% growth, while operating margin expansion is projected between 50 and 75 basis points. Regionally, the United States showed robust 11% organic growth with five out of eight business units achieving double-digit growth.